BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Millan MJ, Gobert A, Panayi F, Rivet JM, Dekeyne A, Brocco M, Ortuno JC, Di Cara B. The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Int J Neuropsychopharmacol 2008;11:1105-22. [PMID: 18466669 DOI: 10.1017/S1461145708008894] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Potter LE, Burgess CR. The melanin-concentrating hormone system as a target for the treatment of sleep disorders. Front Neurosci 2022;16:952275. [DOI: 10.3389/fnins.2022.952275] [Reference Citation Analysis]
2 Kupcova I, Danisovic L, Grgac I, Harsanyi S. Anxiety and Depression: What Do We Know of Neuropeptides? Behavioral Sciences 2022;12:262. [DOI: 10.3390/bs12080262] [Reference Citation Analysis]
3 Li M, Li T, Xiao X, Chen J, Hu Z, Fang Y. Phenotypes, mechanisms and therapeutics: insights from bipolar disorder GWAS findings. Mol Psychiatry. [DOI: 10.1038/s41380-022-01523-9] [Reference Citation Analysis]
4 Rana T, Behl T, Sehgal A, Singh S, Sharma N, Abdeen A, Ibrahim SF, Mani V, Iqbal MS, Bhatia S, Abdel Daim MM, Bungau S. Exploring the role of neuropeptides in depression and anxiety. Prog Neuropsychopharmacol Biol Psychiatry 2022;114:110478. [PMID: 34801611 DOI: 10.1016/j.pnpbp.2021.110478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
5 Myslivecek J. Social Isolation: How Can the Effects on the Cholinergic System Be Isolated? Front Pharmacol 2021;12:716460. [PMID: 34916930 DOI: 10.3389/fphar.2021.716460] [Reference Citation Analysis]
6 Bicks LK, Koike H, Akbarian S, Morishita H. Prefrontal Cortex and Social Cognition in Mouse and Man. Front Psychol 2015;6:1805. [PMID: 26635701 DOI: 10.3389/fpsyg.2015.01805] [Cited by in Crossref: 192] [Cited by in F6Publishing: 181] [Article Influence: 27.4] [Reference Citation Analysis]
7 Schmidt FM, Kratzsch J, Gertz HJ, Tittmann M, Jahn I, Pietsch UC, Kaisers UX, Thiery J, Hegerl U, Schönknecht P. Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. PLoS One 2013;8:e63136. [PMID: 23667582 DOI: 10.1371/journal.pone.0063136] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
8 Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8:287-304. [PMID: 21358978 DOI: 10.2174/157015910792246227] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 6.6] [Reference Citation Analysis]
9 Chung S, Parks GS, Lee C, Civelli O. Recent updates on the melanin-concentrating hormone (MCH) and its receptor system: lessons from MCH1R antagonists. J Mol Neurosci 2011;43:115-21. [PMID: 20582487 DOI: 10.1007/s12031-010-9411-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
10 Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77. [PMID: 19110199 DOI: 10.1016/j.nurt.2008.10.039] [Cited by in Crossref: 140] [Cited by in F6Publishing: 130] [Article Influence: 10.8] [Reference Citation Analysis]
11 Nagasaki H, Chung S, Dooley CT, Wang Z, Li C, Saito Y, Clark SD, Houghten RA, Civelli O. The pharmacological properties of a novel MCH1 receptor antagonist isolated from combinatorial libraries. Eur J Pharmacol 2009;602:194-202. [PMID: 19041642 DOI: 10.1016/j.ejphar.2008.10.068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]